Toward a strategy to involve patients in health technology assessment in Spain

14 March 2019 - The aim of this study was to develop a feasible and effective strategy to involve patients in ...

Read more →

Patient advocacy groups in Canada with ties to pharma are big boosters for government coverage

5 March 2019 - As the interplay between the pharmaceutical industry and patient advocacy groups undergoes stepped-up scrutiny, a new ...

Read more →

Evaluating Canadians’ values for drug coverage decision making

2 March 2019 - Decision makers are facing growing challenges in prioritising drugs for reimbursement because of soaring drug costs and ...

Read more →

How big pharma donations may influence public drug coverage

21 February 2019 - A new review of 372 patient group submissions to the CADTH – about whether new medicines should ...

Read more →

Medicines for rare disorders

13 February 2019 - PHARMAC is working on policy and funding for medicines for rare disorders. ...

Read more →

Determining value in health technology assessment: stay the course or tack away?

15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...

Read more →

Rationing of health care in the United States; an inevitable consequence of increasing health care costs

13 February 2019 - The modern era of medicine began in the 1960s. Health care coverage expanded with the passage ...

Read more →

PHARMAC to review its practices following criticism of breast cancer drug funding

13 February 2019 - The government's drug-buying agency has announced it has begun an internal review following a petition and ...

Read more →

How procurement judges the value of medical technologies: a review of health care tenders

8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...

Read more →

Patient involvement in reflective multi-criteria decision analysis to assist decision making in oncology

7 February 2019 - Patient involvement in drug evaluation decision making is increasing.  ...

Read more →

Time for inquiry into PHARMAC's funding of cancer drugs

4 February 2019 - Labour promised voters world class cancer care but, of all the rocks I've looked under, I ...

Read more →

FDA chief Scott Gottlieb warns 'we have many hard decisions ahead of us' if government shutdown persists

18 January 2019 - "We are in uncharted territory. This is a watershed moment in the life of this agency," he ...

Read more →

Reducing the expert halo effect on Pharmacy and Therapeutics Committees

18 January 2019 - At a recent pharmacy and therapeutics committee meeting, a highly respected specialist presented a novel haemostatic drug ...

Read more →

Decision criteria that influence managed entry agreements

3 January 2019 - Managed entry agreements enable payers to subsidise access to new medicines while addressing uncertainties.  ...

Read more →

ICER describes for patients and policy makers why the QALY is considered the best way to reward the care that improves patients’ lives

12 December 2018 - ICER reiterates its commitment to equality and will highlight measures of cost-effectiveness that value any extension of ...

Read more →